Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Arizona: - Kingman Regional Medical Center — Kingman, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
Phase 3 Recruiting Academic/Other
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather tha…
Sponsor: NRG Oncology
NCT ID: NCT03801876
Sites in Arizona: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Arizona: - Research Site — Phoenix, Arizona
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gast…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221149
Sites in Arizona: - Local Institution - 0284 — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Arizona: - Research Site 111 — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Arizona: - Mayo Clinic-Arizona — Phoenix, Arizona
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Arizona: - Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Arizona: - Clinical Trial Site — Phoenix, Arizona
- Clinical Trial Site — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Arizona: - University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…
Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Arizona: - Mayo Foundation for Medical Education and Research - Mayo Cl — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ra…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06445972
Sites in Arizona: - University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927) — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05319730
Sites in Arizona: - University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) — Tucson, Arizona
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about th…
Sponsor: I-Mab Biopharma US Limited
NCT ID: NCT07432295
Sites in Arizona: - I-Mab Site 1016 — Goodyear, Arizona
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Arizona: - The University of Arizona Cancer Center — Tucson, Arizona
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT07021066
Sites in Arizona: - Mayo Clinic Cancer Center- Phoenix — Phoenix, Arizona
- HonorHealth — Scottsdale, Arizona
Phase 1 Recruiting Industry
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid …
Sponsor: Plexium, Inc.
NCT ID: NCT07284186
Sites in Arizona: - Research Site — Scottsdale, Arizona
Phase 1 Recruiting Industry
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is avail…
Sponsor: Kyowa Kirin Co., Ltd.
NCT ID: NCT06266299
Sites in Arizona: - Mayo Clinic Arizona — Scottsdale, Arizona
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arizona: - Kingman Regional Medical Center — Kingman, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Arizona: - Cancer Center at Saint Joseph's — Phoenix, Arizona
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arizona: - Massive Bio SYNERGY-AI site — Scottsdale, Arizona
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Arizona: - Ironwood Cancer & Research Centers — Chandler, Arizona
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Arizona: - Research Site — Casa Grande, Arizona
NA Recruiting Academic/Other
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampli…
Sponsor: University of Colorado, Denver
NCT ID: NCT05530343
Sites in Arizona: - Arizona Centers of Digestive Health — Gilbert, Arizona
NA Recruiting Academic/Other
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux d…
Sponsor: Mayo Clinic
NCT ID: NCT03961945
Sites in Arizona: - Mayo Clinic Arizona — Scottsdale, Arizona
NA Recruiting Academic/Other
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devi…
Sponsor: Mayo Clinic
NCT ID: NCT06071845
Sites in Arizona: - Mayo Clinic — Scottsdale, Arizona